AtaiBeckley (ATAI) surged 28% fuelled by Trump's executive order to fast-track psychedelic reviews and his $50 million push to federal research into the psychedelic compound called ibogaine. Canaccord raised its price target to $15. The company is preparing BPL-003 for late-stage trials this quarter. The move also boosted shares of peers like Compass Pathways and Psyence Biomedical.